JY
FRTX

Jeff Yass’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Jeff Yass’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-749
Closed -$4K – 14419
2022
Q2 		$4K Sell
749
-2,086
-74% -$18.9K ﹤0.01% 12638
2022
Q1 		$34K Buy
2,835
+503
+22% +$5.44K ﹤0.01% 12467
2021
Q4 		$24K Buy
+2,332
New +$41.9K ﹤0.01% 12796
2020
Q3 		– Sell
-468
Closed -$21K – 11320
2020
Q2 		$21K Buy
+468
New +$24.9K ﹤0.01% 9915
2019
Q2 		– Sell
-75
Closed -$25.1K – 11000
2019
Q1 		$28K Buy
75
+15
+25% +$5.03K ﹤0.01% 8557
2018
Q4 		$22K Sell
60
-120
-67% -$47.1K ﹤0.01% 8667
2018
Q3 		$78K Buy
180
+37
+26% +$15.6K ﹤0.01% 8695
2018
Q2 		$52K Buy
+143
New +$67.3K ﹤0.01% 9264
2018
Q1 		– Sell
-33
Closed -$19K – 10394
2017
Q4 		$19K Buy
+33
New +$21.7K ﹤0.01% 9073
2016
Q4 		– Sell
-49
Closed -$47K – 10317
2016
Q3 		$47K Buy
+49
New +$61.8K ﹤0.01% 8139
2015
Q3 		– Sell
-4
Closed -$7.72K – 10348
2015
Q2 		$9K Buy
+4
New +$12.5K ﹤0.01% 10037
2014
Q3 		– Sell
-11
Closed -$42.7K – 10058
2014
Q2 		$41K Hold
11
– – ﹤0.01% 9620
2014
Q1 		$43K Hold
11
– – ﹤0.01% 8725
2013
Q4 		$39K Buy
+11
New +$41.7K ﹤0.01% 8837

Other funds holding FRTX

TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's FRTX Position: Q3 2022 in Review

Jeff Yass sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2022, closing a stake of 749 shares — an estimated $4K sold.

Jeff Yass first reported a position in FRTX in Q4 2013 and held it in 14 quarters. The position peaked at $78K in Q3 2018. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2022.

  • Jeff Yass reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Jeff Yass sold 749 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
  • Jeff Yass first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2013 and held it in 14 quarters.
  • Jeff Yass's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $78K in Q3 2018.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.